OPTHEA LTD

Research OPTHEA LTD (UKJ) on Bullrun: market cap EUR 8.89M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerUKJ
• ExchangeF
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 8.89M
• Financial periodFY2025
• RevenueEUR 25.00K
• Revenue growth-80.0%
• Net income-EUR 162.79M
• Free cash flow-EUR 158.66M

Valuation Snapshot

latest market cap is EUR 8.89M.

About OPTHEA LTD

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries.

Frequently asked questions

What is OPTHEA LTD's market cap?

OPTHEA LTD's market capitalization is EUR 8.89M.

What does OPTHEA LTD do?

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.